Minimal Disease Activity as a Therapeutic Goal in Atopic Dermatitis: Predictive Factors of Sustainability in a Multicenter Cohort [0.03%]
特应性皮炎治疗目标达到最小疾病活动度的预测因素：多中心队列研究
Francisco Javier Melgosa Ramos,Santiago Guillén Climent,Marta Galarreta Pascual et al.
Francisco Javier Melgosa Ramos et al.
Introduction: Minimal disease activity (MDA) is an emerging therapeutic goal in atopic dermatitis (AD), providing a multidimensional assessment of disease control. ...
Real-World Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A 16-Week Single-Center Retrospective Cohort Study Compared with Upadacitinib and Baricitinib [0.03%]
阿布昔替尼治疗特应性皮炎患者的有效性和安全性：一项与乌帕替尼和巴瑞克替尼对比的16周单中心回顾性队列研究
Ho Eun Gwag,Minjung Park,So Yun Park et al.
Ho Eun Gwag et al.
Introduction: Abrocitinib, a selective Janus kinase (JAK)-1 inhibitor, is approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although several real-world studies evaluated the safety and efficacy of a...
Pathological Insights into the Limitations of Clinical and Dermoscopic Evaluations in Monitoring Sonidegib Treatment Response for Locally Advanced Basal Cell Carcinoma: A Real-World Study [0.03%]
病理学视角下的临床和皮肤镜评估在监测索那非克治疗局部晚期基底细胞癌疗效中的局限性：一项真实世界研究
Xurong Liu,Jipang Zhan,Jingwen Zou et al.
Xurong Liu et al.
Introduction: Surgical excision is the standard treatment for basal cell carcinoma (BCC). For locally advanced BCC (laBCC) not suitable for surgery or radiotherapy, Hedgehog pathway inhibitors (HHIs) such as sonidegib are...
Systemic Corticosteroid Exposure in Patients with Atopic Dermatitis: A US Population-Based Study [0.03%]
美国人口为基础的特应性皮炎患者系统性糖皮质激素暴露研究
Christopher G Bunick,Ruth Ann Vleugels,Mark Lebwohl et al.
Christopher G Bunick et al.
Introduction: Clinical guidelines recommend against routine use of systemic corticosteroids in atopic dermatitis (AD) due to associated adverse effects. Real-world adherence to these guidelines is unclear. ...
Dermoscopy of Prurigo Nodularis/Lichen Simplex Chronicus of the Scalp: A Comparative Observational Study in Fair and Dark Skin [0.03%]
头皮瘙痒性结节/慢性单纯性苔藓表皮镜检查的比较观察研究：浅色和深色皮肤患者的对比研究
Noemi Plozner,Michela Lai,Nkechi A Enechukwu et al.
Noemi Plozner et al.
Introduction: Although recognition of prurigo nodularis (PN) and lichen simplex chronicus (LSC) of the scalp is usually straightforward, they may sometimes pose difficulties in terms of differential diagnosis with other s...
Eva Vilarrasa,Joaquín Borrás-Blasco,Silvia Lobo-Benito et al.
Eva Vilarrasa et al.
Introduction: Hidradenitis suppurativa (HS) is a highly disabling chronic inflammatory disorder affecting up to 1% of the Spanish population. It is a complex disease that requires significant resources and imposes a consi...
Upadacitinib for Atopic Dermatitis Involving Special and Sensitive Areas: Real-World Multicenter Outcomes in Hand, Head/Neck, and Genital Involvement [0.03%]
优瑞克利姆治疗特应性皮炎手部、头颈部和外生殖器受累的现实世界多中心结果分析研究
Francisco Javier Melgosa Ramos,Santiago Guillén-Climent,Raquel Cavestany Rodriguez et al.
Francisco Javier Melgosa Ramos et al.
Introduction: Atopic dermatitis (AD) involving special areas such as the hands, head and neck, and genital region poses important therapeutic challenges owing to distinct barrier fragility, environmental exposure, and mix...
Sun Tattoos and Social Media: A Behavioral Dermatology Perspective on Emerging Photodamage Trends [0.03%]
晒伤与社交媒体：行为皮肤学视角下的新兴光老化趋势
Diala Haykal,Brigitte Dréno,Thierry Passeron
Diala Haykal
Sun tattoos, also referred to as patterned sunburn lines, have recently emerged as a visible consequence of uneven ultraviolet (UV) exposure, increasingly shared on social media platforms, particularly by adolescents and young adults. These...
Remibrutinib Showed a Favorable Safety Profile and Sustained Efficacy in Japanese Patients with Chronic Spontaneous Urticaria Over 52 Weeks [0.03%]
瑞米普利单抗治疗慢性自发性荨麻疹日本患者52周后安全性良好且疗效持续
Koremasa Hayama,Yuko Chinuki,Akiko Yagami et al.
Koremasa Hayama et al.
Introduction: Remibrutinib, an oral, highly selective, Bruton's tyrosine kinase (BTK) inhibitor, has shown efficacy and favorable safety in pivotal global phase 3 studies in patients with chronic spontaneous urticaria (CS...
Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE Study [0.03%]
意大利使用DASS-21问卷的BLUE研究：一项多中心观察性研究中治疗中至重度斑块状银屑病患者的心理幸福感：28周中期结果
Emanuele Trovato,Claudio Bonifati,Simone Ribero et al.
Emanuele Trovato et al.
Introduction: Psoriasis is a chronic inflammatory skin disease associated with significant physical and psychological burden. Tildrakizumab, an interleukin-23 p19 inhibitor, has demonstrated efficacy in treating moderate-...